BCDA compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

BCDABioCardia, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

BCDABioCardia, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

BCDABioCardia, Inc.

0.88▼−2.31%· post 0.92· delayed

Mkt cap$13.7MRevenue$55,000Q1 FY24Revenue—

AMGNAmgen Inc

460.67▼−1.03%· post 453.11· delayed

After hoursNov 3 '26delayed

Mkt cap$251.6BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

Compare

After hoursNov 3 '26delayed

BCDABioCardia, Inc.

AMGNAmgen Inc

0.88▼−2.31%post 0.92delayed

Price

460.67▼−1.03%post 453.11delayed

$13.7M

Mkt cap

$251.6B

Q1 FY24$55,000

Revenue

$10.1BQ2 FY26

—

Revenue

$36.8BFY25

BCDA0.88▼−2.31%vsAMGN460.67▼−1.03%After hoursNov 3 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

BCDA: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only BCDA 0

None

Shared 0

No disclosed counterparties: BCDA.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Role chip = supplier or customerSource: SEC EDGAR

Price

rebased to 0%

BCDA, solidAMGN, dashed